Portfolio

TolerogenixX

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.

Pressemeldungen

TolerogenixX secures seed funding and completes Phase I clinical trial

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. In a Phase I…
Read

Info & Contact

Dr. Matthias Schaier
Phone:
+49 6221 5639930
Web:
www.tolerogenixx.com

Address

TolerogenixX GmbH
Im Neuenheimer Feld 162
69120 Heidelberg

In portfolio

21. Dec 2016